House committees to investigate new Alzheimer’s disease drug approval
Jul 01, 2021
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
Antidepressants not tied to long-term boost in quality of life
Apr 20, 2022
No improvement seen in physical or mental health-related quality of life
Brain-training app aids cognitive function after brain injury
Aug 13, 2021
Cognitive improvement seen in vets using self-administered program remotely for 12 weeks, with results sustained for an additional 12 weeks
USPSTF still advises against COPD screening for asymptomatic adults
Nov 02, 2021
There is no net benefit for screening asymptomatic adults for COPD, the U.S. Preventive Services Task Force has concluded in its latest recommendation.
Statin initiation linked to greater progression of diabetes
Oct 04, 2021
Each individual component of the composite outcome was significantly higher among statin users
USPSTF: Evidence lacking for glaucoma screening in adults
May 24, 2022
The U.S. Preventive Service Task Force concludes that the evidence is currently insufficient to assess the balance of benefits and harms for screening for glaucoma in asymptomatic adults and for impaired...
USPSTF updates guidance on statins for primary prevention of CVD
Feb 22, 2022
Statin use recommended for people aged 40 to 75 years with CV risk factor(s) and higher 10-year risk for a CV event
DEA extends telemedicine for prescribing controlled meds as pandemic measures end
May 10, 2023
Extension through Nov. 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1
COVID-19 rapid test makers struggling to meet demand
Jan 21, 2022
However, government’s order for the free test kits is in addition to existing supply and does not interfere with existing orders
USPSTF recommends biennial screening mammography from ages 40 to 74
May 10, 2023
New draft recommendations advocate starting biennial mammographies at age 40. Evidence said to be insufficient for screenings in women aged 75 years and older.